In 2024, Robert M. Davis earned $20.28M in total compensation at Merck & Co., including $1.62M salary and $18.10M in stock. Most recently acquired 95,275 shares in Jan 2025. Currently holds stock worth $48.58M. 4+ years at the helm of Merck & Co..
Compensation History
Annual executive compensation data for Robert M. Davis, including salary, bonuses, and stock awards.
Year
2024
Total Compensation
$20.28M
Salary
$1.62M
Bonus
$0.00
Other
$561.11K
Salary
$1.62MBoard Justification
We strive to deliver market-competitive pay within a framework that provides an appropriate mix of fixed and variable, at-risk compensation to attract, retain, and motivate talent and align with our pay-for-performance objectives.
Bonus
$0.00Board Justification
N/A
Other Compensation
$561.11KBoard Justification
Includes financial/tax counseling, company aircraft, company car and driver, installation, maintenance, residential security, travel security, and remote access of home security, and savings plan company match and credits.
Restricted Stock
Board Justification
PSUs granted in 2022 that were paid on January 27, 2025, including dividends accrued and paid in shares.
Performance Metrics
Top and bottom-line performance, Pipeline accomplishments, Achievement of strategic sustainability priorities, Decision-making that yields long-term value creation for shareholders, Executing on our growth strategy
Robert M. Davis
CEO of Merck & Co.
Education
Not specified
Field of Expertise
Finance & Banking - Finance
Sector of Economy
Healthcare
Born
April 19, 1966 - 59 years ago
CEO of Merck & Co. for
4 years 5 months (Jul 2021 - Present)
Previous Experience
Chief Financial Officer at Baxter International
Other Merck & Co. CEOs
Holdings
Track Robert M. Davis's stock holdings and portfolio value over time.
Total Stock Sold
$133.57M
$117.83M
1,206,526 MRK shares
$15.74M
231,800 BAX shares
What if they kept their stock?
If Robert M. Davis didn't sell their stock, today they would have:
Extra MRK1,206,526 shares worth $121.73M and BAX231,800 shares worth $4.28M.
This is -5.66% and $7.56M less than what they got when they sold the stock.
Insider Trading
Robert M. Davis's recent stock transactions, purchases, and sales filed with the SEC.
$9.33M
MRK at $97.94/share
Jan 27, 2025
Received
$29.57M
MRK at $125.84/share
Feb 13, 2024
Sale
$9.14M
MRK at $119.43/share
Jan 22, 2024
Received
$16.47M
MRK at $114.93/share
Apr 28, 2023
Sale
$2.66M
MRK at $109.88/share
Jan 23, 2023
Received
$17.24M
MRK at $102.84/share
Nov 9, 2022
Sale
$2.20M
MRK at $73.51/share
Feb 24, 2022
Received
$3.39M
MRK at $72.62/share
Feb 26, 2021
Received
$20.36M
MRK at $81.03/share
Oct 5, 2020
Sale
$2.56M
MRK at $76.56/share
Feb 28, 2020
Received
Rivals
Compare Robert M. Davis with competitor CEOs and industry peers.
Albert Bourla
CEO of Pfizer
2024 Compensation
Stock
$0.00
Salary
$1.80M
Bonus
$7.02M
Other
$996.06K
Total Holdings
$18.14M
Daniel O'Day
CEO of Gilead Sciences
2024 Compensation
Stock
$18.79M
Salary
$1.77M
Bonus
$0.00
Other
$1.34M
Total Holdings
$23.48M
Joseph K. Belanoff, M.D.
Founder and CEO of Corcept Therapeutics
2023 Compensation
Stock
$0.00
Salary
$1.10M
Bonus
$1.32M
Other
$22.50K
Total Holdings
$21.20M
Joaquin Duato
CEO of Johnson & Johnson
2024 Compensation
Stock
$7.13M
Salary
$1.60M
Bonus
$3.22M
Other
$1.08M
Total Holdings
$1.09M
Stéphane Bancel
CEO of Moderna
2023 Compensation
Stock
$0.00
Salary
$1.58M
Bonus
$1.91M
Other
$1.07M
Total Holdings
$335.71M
Christopher Boerner
CEO of Bristol-Myers Squibb
2023 Compensation
Stock
$0.00
Salary
$1.50M
Bonus
$0.00
Other
$311.64K
Total Holdings
$7.39M